Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $162M (up 106.9% year over year) with net income of −$7M.
Q1 2026 key financials · XBRL
- Revenue
- $162M
- +106.9% YoY
- Net income
- −$7M
- +72.3% YoY
- Operating margin
- -3.8%
- EPS (diluted)
- −$0.16
- +75.0% YoY
Source: XBRL data from the Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 10-Q on SEC EDGAR. USD.
Tarsus Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $162.1M, up $83.7M YoY from $78.3M, including $145.4M XDEMVY sales
- Gross margin 94% vs 93% YoY; net loss $7.0M vs $25.1M
- XDEMVY best performer, sales $145.4M, up more than 85% YoY
- Cash, equivalents and marketable securities $388.7M at March 31, 2026
- TP-04 and TP-05 topline results expected first half 2027; macroeconomic volatility and trade tensions remain headwinds
Risk Factors
- Newly highlighted cybersecurity risk from AI use, including sensitive-data processing that may be difficult to monitor or secure
- Most materially updated tariff risk following a 10% global tariff effective February 24, 2026 and pharmaceutical tariffs up to 100%
- Regulatory and compliance exposure from privacy breaches, including potential CCPA lawsuits and mandatory corrective action
- Commercial risk from inflation, reimbursement pressure, and patient cost sensitivity reducing XDEMVY demand
- Financial risk from continued losses, including $7.0 million net loss and $433.6 million accumulated deficit as of March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tarsus Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.